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Background. Several diagnostic laboratory methods are available for case confirmation of Buruli ulcer disease.
This study assessed the sensitivity of various diagnostic tests in relation to clinical presentation of the disease, type
of diagnostic specimen, and treatment history.
Methods. Swab samples, 3-mm punch biopsy tissue specimens, and surgically excised tissue specimens from
384 individuals with suspected Buruli ulcer disease were obtained at 9 different study sites in Ghana and were
evaluated with dry reagent–based polymerase chain reaction (PCR), microscopic examination, culture, and his-
topathological analysis. The study subjects presented with nonulcerative and ulcerative lesions and were divided
into 3 treatment groups: (1) previously untreated patients scheduled for antimycobacterial treatment, (2) patients
treated with surgery alone, and (3) patients treated with surgery in combination with previous antimycobacterial
treatment.
Results. Of 384 suspected cases of Buruli ulcer disease, 268 were confirmed by at least 1 positive test result.
The overall sensitivity of PCR (85%) was significantly higher than that of microscopic examination (57%) and
culture (51%). After data were stratified by treatment group, type of lesion, and diagnostic specimen type, analysis
revealed that PCR of 3-mm punch biopsy tissue specimens (obtained from previously untreated nonulcerative
lesions) and of swab samples (obtained from previously untreated ulcers) had the highest diagnostic sensitivity
(94% and 90%, respectively). Although duration of the disease did not significantly influence the sensitivity of
any test, previous antimycobacterial treatment was significantly associated with decreased sensitivity of PCR and
culture.
Conclusions. Across all subgroups, PCR had the highest sensitivity. PCR assessment of 3-mm punch biopsy
tissue specimens proved to be the best diagnostic tool for nonulcerative lesions, and PCR assessment of swab
samples was the best diagnostic tool for ulcerative lesions. For monitoring of antimycobacterial treatment success
within controlled trials, however, only culture is appropriate.
Buruli ulcer disease (BUD), which is caused by My-
cobacterium ulcerans, affects the skin and subcutaneous
adipose tissue. BUD occurs in 130 countries worldwide,
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with a focus and an increasing number of cases oc-
curring in West Africa [1–3]. The disease initially pre-
sents as a painless nodule, papule, plaque, or edema
and evolves into a painless ulcer with characteristically
undermined edges. If untreated, scarring and contrac-
tures may cause serious functional disabilities [3, 4].
Previously, BUD was treated with wide surgical exci-
sion; in 2004, however, antimycobacterial treatment
alone or in combination with surgery was introduced
[3–8]. Currently available diagnostic laboratory tests
include microscopic examination, culture, IS2404 PCR
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of swab samples and tissue specimens, and histopathological
analysis.
According to various studies of the laboratory confirmation
of clinically suspected cases of BUD, microscopic examination
detects 29%–78% of BUD cases, and culture detects 34%–79%.
Antimycobacterial treatment before specimen collection was
shown to reduce culture positivity ratios (i.e., the number of
positive test results divided by the number of cases of clinically
suspected BUD) to !5%. Histopathological analysis confirmed
190% of clinically diagnosed BUD cases and 170% of clinically
suspected BUD cases [8–15].
With an analytical specificity of 100% [16–19], a sensitivity
of 79%–85% [10,12], and positivity ratios of 61%–72% [14,
15], IS2404 PCR is considered to be the most reliable technique
for the detection of M. ulcerans in human diagnostic samples.
Laboratory assessment of nonulcerative lesions is restricted to
an analysis of tissue specimens, whereas diagnostic swab sam-
ples provide a valuable alternative for assessment of ulcerative
lesions. According to recent data from Ghana, microscopic ex-
amination and/or PCR of swab samples allowed confirmation
of up to 70% of suspected cases of BUD [14, 20].
In 2001, the World Health Organization recommended that
2 positive laboratory test results be obtained to confirm a pos-
itive diagnosis [21]. However, laboratory confirmation of sus-
pected cases of BUD by 1 positive test result yields ∼20% more
confirmed cases than does confirmation by 2 positive test re-
sults. Because of the high positive predictive values of IS2404
PCR (100%) and microscopic examination (97%), 1 positive
test result is considered to be sufficient for confirmation of a
diagnosis of BUD [14, 20]. A positive IS2404 PCR result is also
regarded as adequate evidence to commence antimycobacterial
treatment [22].
In addition to swab samples, punch biopsy tissue specimens
also allow the pretreatment laboratory confirmation of sus-
pected BUD [3, 22]. Data on the diagnostic use of punch biopsy
tissue specimens, however, are still scarce. Phillips et al. [23]
reported sensitivities of 42% for microscopic examination, 49%
for culture, 98% for IS2404 PCR, and 82% for histopathological
analysis of 4-mm and 6-mm punch biopsy tissue specimens.
In the context of a research program funded by the European
Commission on diagnosis and antimycobacterial treatment of
BUD, various types of diagnostic specimens were obtained from
patients who presented with different clinical forms of the dis-
ease and were grouped into 3 different treatment categories.
The aim of this study was to determine the sensitivities of
diagnostic laboratory methods for various types of specimens,
depending on the type of lesions and prior treatment history.
PATIENTS, MATERIALS, AND METHODS
Study population and inclusion criteria. The study included
individuals with clinical suspicion of BUD who had nonulcer-
ative or ulcerative lesions and were seen from January 2006
through February 2008 at 9 different study sites in Ghana. The
study subjects belonged to 1 of 3 different treatment groups:
(1) the drug treatment group, which included patients who
were scheduled for drug treatment, had received no antimy-
cobacterial treatment before specimen collection, had a 6-
month duration of disease, had lesions 10 cm in diameter,
and were 5 years of age; (2) the surgical treatment group,
which included patients who were treated with surgical excision
and had received no previous antimycobacterial treatment; and
(3) the surgical treatment plus antimycobacterial treatment
group, which included patients who were treated with surgical
excision and had received at least 7 days of previous antimy-
cobacterial treatment.
Standardized specimen collection. In the majority of cases,
the diagnostic specimens were collected during the patients’
initial presentation to the hospital. For a limited number of
patients, additional follow-up samples were analyzed. Swab
samples were taken by circling the entire undermined edges of
ulcerative lesions. Three-millimeter punch biopsy tissue spec-
imens and surgically excised tissue specimens with a maximum
size of 1010 mm were taken from the center of nonulcerative
lesions or from undermined edges of ulcerative lesions, in-
cluding necrotic tissue [20, 24].
The following sets of specimens were taken: for those in the
drug treatment group with nonulcerative lesions, 3 punch bi-
opsy specimens; for those in the drug treatment group with
ulcerative lesions, 2 swab samples and 3 punch biopsy speci-
mens; for those in the surgical treatment group and surgical
treatment plus antimycobacterial treatment group with non-
ulcerative lesions, 3 surgically excised tissue specimens; and for
those in the surgical treatment group and surgical treatment
plus antimycobacterial treatment group with ulcerative lesions,
2 swab samples and 3 surgically excised tissue specimens ob-
tained during the surgical procedure (figure 1). Standardized
specimen collection bags, including containers with transport
and storage media and data entry forms (BU01 and laboratory
data entry form [3]) were provided to the study sites. PCR
specimens were collected in 700 mL of cell lysis solution (Gentra
Systems), culture specimens were collected in 5 mL of PANTA
(polymyxin B, amphotericin B, nalidixic acid, trimethoprim,
and azlocillin), and histological specimens were collected in 5
mL of 10% buffered neutral formalin [14, 20].
Diagnostic methods and laboratories. Diagnostic speci-
mens were processed at the Kumasi Centre for Collaborative
Research in Tropical Medicine in Kumasi, Ghana, by dry re-
agent–based IS2404 PCR, microscopic examination, and cul-
ture with use of standardized procedures [14, 19–21]. Standard
IS2404 PCR was performed and slides were reread for external
quality assurance by the Department for Infectious Diseases
and Tropical Medicine at the University of Munich (Munich,
Figure 1. Flow chart of the study procedure. Specimens (swab samples [swab], punch biopsy tissue specimens [tissue-punch], and surgically excised
tissue specimens [tissue-surgery]) obtained from 384 patients with suspected Buruli ulcer disease (BUD) from 3 different treatment groups (drug
treatment [DT], surgical treatment without previous antimycobacterial treatment [ST], and surgical treatment with previous antimycobacterial treatment
[ST+]) for BUD diagnostic testing with dry reagent–based IS2404 PCR (PCR), microscopy (MIC), culture with confirmatory IS2404 dry reagent–based
PCR (CUP), and histopathologcial analysis (HIS). There were a total of 268 laboratory-confirmed cases of BUD (A) and 116 suspected cases of BUD
without laboratory confirmation (B). The statistics are based on the data obtained from each patient’s first lesion (if there was 11 lesion per patient)
and each patient’s first visit at hospital (if there was 11 visit per patient). *Four of 16 patients with suspected BUD who had negative findings at
initial presentation (3 in the ST group and 1 in the DT group) had BUD confirmed at follow-up visits. **Twenty-six of 44 patients in the DT group
with suspected BUD that was not laboratory confirmed (15 patients with nonulcerative lesions and 29 patients with ulcerative lesions) received
antimycobacterial treatment, because the clinical findings were suggestive of BUD. Three additional patients with suspected BUD in the DT group
received treatment for onchocerciasis. The remaining 15 patients in the DT group with suspected BUD were lost to follow-up.
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Germany), and histopathological examination was performed
at the Bernhard Nocht Institute for Tropical Medicine (Ham-
burg, Germany) and the Department of Pathology at the Uni-
versity of Munich [11, 17, 24].
In brief, DNA was prepared using the Puregene DNA iso-
lation kit, with minor modifications [19]. For dry reagent–
based PCR, the oligonucleotides MU5 and MU6 [17] were
lyophilized in reaction tubes. PuReTaqTM Ready-To-GoTM
PCR Beads (Amersham Biosciences) were added and dissolved
in water before adding the template DNA. The standard PCR
was performed according to the protocol described by Stinear
et al. [17]. Both PCR assays included negative extraction and
positive, negative, and inhibition controls.
Culture specimens were decontaminated by the Petroff
method, inoculated on Loewenstein-Jensen media, and incu-
bated at 32C for 6 months. Microscopy smears were prepared
from decontaminated material and were stained with the Ziehl-
Neelsen technique [22].
Cultures with growth were subjected to Ziehl-Neelsen stain-
ing and a confirmatory IS2404 PCR. If a negative PCR result
was obtained, sequence analysis of the rpoB gene (342 base
pairs), 16S–23Sribosomal RNA (rRNA) internal transcribed
spacer gene (220 base pairs), 16S rRNA gene (924 base pairs),
and 65-kDa HSP gene (644 base pairs) was performed for strain
identification [25–28].
Definition of sensitivity for each individual test. In this
study, the sensitivity of a certain test was defined as the number
of positive test results divided by the number of patients with
at least 1 positive result of any diagnostic test [14, 20].
Statistical analysis. Approximative tests (x2 tests), exact
tests (Fisher’s exact tests), and Student’s t tests as parametric
test were conducted using Stata software, version 9.0 (Stata).
Statistically significant differences were defined as P values !.05
or as nonoverlapping 95% CIs of proportions. Dependent var-
iables were diagnostic test results. Type of lesion, duration of
disease, duration of antimycobacterial treatment (if conducted
before specimen collection), and type of diagnostic specimen
were independent variables.
Ethical clearance and informed patient consent. Ethical
clearance for the study was sought through the Committee of
Human Research Publication and Ethics, Kwame Nkrumah
University of Science and Technology, and the Komfo Anokye
Teaching Hospital, Kumasi, Ghana. Informed patient consent
was used for patients who received drug treatment and for
patients who underwent surgical procedures.
RESULTS
Subjects. Four hundred sets of specimens from 384 individ-
uals with suspected BUD (drug treatment group, 204 patients;
surgical treatment group, 109 patients; and surgical treatment
plus antimycobacterial treatment group, 71 patients) who pre-
sented with 140 nonulcerative (35%) and 260 ulcerative (65%)
lesions were collected at the first presentation at the hospital.
Sixteen patients had 2 lesions. A total of 43 sets of follow-up
specimens were obtained from 30 study subjects; however, only
data from the patients’ initial specimen collection were con-
sidered for analysis. Forty-eight percent of the suspects were
5–14 years of age (age range, 1–95 years; mean age, 21 years;
median age, 14 years); 40.9% of the patients were male (figure
1).
Laboratory-confirmed BUD cases. One hundred seventy-
two (44%) of the BUD cases were confirmed by at least 2
positive laboratory test results; 268 (69.8%) were confirmed by
at least 1 positive laboratory test result (figure 1). One hundred
fourteen (42.5%) of the patients with BUD presented with
nonulcerative lesions, and 154 (57.5%) presented with ulcer-
ative lesions; 108 (40.3%) of the patients were male, and 150
(56.6%) of 265 patients (for 3 patients, age was unknown) were
5–14 years of age (range, 2–80 years; mean age, 18 years; median
age, 12 years) (figure 2). In 231 (93.1%) of 248 patients, the
lesions were located on the limbs or shoulders, with the right
side being affected statistically significantly more often (in 138
[59.7%] of 231 patients; ) than the left side (93Pp .035
[40.3%] of 231 patients) (table 1). The lesions of 243 patients
with confirmed cases with known lesion sizes were distributed
according to World Health Organization categories [3], as fol-
lows: category I (a single lesion !5 cm in diameter), 108 patients
(44.4%), including 61 in the drug treatment group, 23 in the
surgical treatment group, and 24 in the surgical treatment plus
antimycobacterial treatment group; category II (a single lesion
5–15 cm in diameter), 127 patients (52.3%), including 93 in
the drug treatment group, 15 in the surgical treatment group,
and 19 in the surgical treatment plus antimycobacterial treat-
ment group; and category III (a single lesion 115 cm in di-
ameter, multiple lesions, or osteomyelitis), 8 patients (3.3%),
including 4 in the drug treatment group, 3 in the surgical
treatment group, and 1 in the surgical treatment plus anti-
mycobacterial treatment group.
Of 268 patients with BUD with at least 1 positive laboratory
test result, 229 (85.4%) had a positive swab sample and/or tissue
specimen with a positive PCR result, and 152 (56.7%) had a
positive swab sample and/or a tissue specimen with positive
microscopy findings. One hundred forty-nine (98.0%) of the
152 specimens with positive microscopy findings had those
findings confirmed by at least 1 of the 3 other tests.
Of the 115 isolates (42.9%) obtained from swab sample and/
or tissue specimen cultures with positive results, 108 isolates
were confirmed by IS2404 PCR (positive predictive value,
93.9%). Among the remaining 7 isolates, sequence analysis
identified 2 M. ulcerans strains. Two further strains were iden-
tified as Mycobacterium mucogenicum and Mycobacterium pho-
caicum, indicating a coinfection or superinfection in 2 indi-
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Table 1. Location of nonulcerative and ulcerative lesions in
248 cases of laboratory-confirmed Buruli ulcer disease.
Specific location
No. (%) of lesions, by general location
(n p 248)
Head
and trunk
Right shoulder
and limbs
Left shoulder
and limbs Total
Head, neck 6 … … 6 (2.4)
Back 7 … … 7 (2.8)
Abdomen 0 … … 0 (0)
Buttock, hip 4 … … 4 (1.6)
Shoulders … 7 6 13 (5.2)
Arms
Overall … 65 39 104 (41.9)
Upper arm … 24 17 41 (16.5)
Forearm … 34 18 52 (21.0)
Wrist … 3 1 4 (1.6)
Hand, dorsal … 3 3 6 (2.4)
Hand, volar … 1 0 1 (0.4)
Legs
Overall … 66 48 114 (46.0)
Thigh … 20 13 33 (13.3)
Knee … 9 7 16 (6.5)
Lower leg … 26 18 44 (17.7)
Ankle … 8 8 16 (6.5)
Foot, dorsal … 3 2 5 (2.0)
Foot, plantar … 0 0 0 (0)
Overall 17 (6.9) 138 (55.6) 93 (37.5) 248 (100)
NOTE. For 20 cases, the specific location of the lesions was not known.
Figure 2. Age distribution of 268 patients with laboratory-confirmed Buruli ulcer disease (BUD). For 3 patients, age was unknown. Age range was
2–80 years, the mean age was 18 years, and the median age was 12 years. For the group of patients who received drug treatment, patients with
suspected BUD who were !5 years of age were not included. For the surgical treatment without previous antimycobacterial treatment group and the
surgical treatment with previous antimycobacterial treatment group, patients with suspected BUD were included regardless of age.
viduals with confirmed BUD. For 3 isolates, sequencing did
not provide definitive identification, probably because of con-
tamination with closely related species that colonize the human
skin.
Among the follow-up samples, sequencing identified 2
strains as Mycobacterium gordonae (cultured from an ulcer with
a swab sample with positive IS2404 PCR) and Mycobacterium
szulgai (isolated from an additional lesion at a different location
on a patient whose initial lesion had a swab sample with positive
IS2404 PCR results).
Histopathological examination confirmed results for 42 of
49 tissue specimens from individuals with otherwise laboratory-
confirmed BUD (sensitivity, 85.7%) and for 17 (29.3%) of 58
specimens from individuals with suspected BUD who had neg-
ative microscopy findings and negative culture and PCR results
(6 [10.3%] of these 58 specimens were obtained from lesions
in the healing stages). In 4 (6.9%) of the 58 individuals with
suspected BUD, histopathological features did not allow an
unambiguous diagnosis, and histological findings in 37 (63.8%)
were not suggestive of BUD (8 of these 37 patients received a
diagnosis of onchocerciasis). Missing or poor-quality specimens
did not allow histopathological analysis for the remaining 75
individuals with suspected BUD.
Of 30 individuals who were followed up over time, 16 re-
ceived laboratory confirmation of BUD at their first presen-
tation to the hospital. Of the remaining 14 subjects, 4 had BUD
confirmed during subsequent follow-up visits. External quality
assurance for microscopic examination and PCR showed 190%
concordance of results (table 2).
Overall sensitivities of laboratory tests among all labora-
tory-confirmed BUD cases. The overall sensitivities were
85.4% (229 of 268 cases) for PCR, 56.7% (152 of 268 cases)
for microscopic examination, and 48.0% (108 of 225 cases) for
culture plus confirmatory IS2404 PCR. The sensitivity of PCR
was significantly higher than that of microscopic examination
and culture plus confirmatory IS2404 PCR ( ), with noP ! .01
statistically significant difference between microscopic exami-
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Table 2. External quality assurance for PCR and microscopic examination.
KCCR result, by method
DITM result
Concordant
results
Concordance
ratio, %aPositive Negative Total
PCRb
Positive 37 0c 37 37 …
Negative 7c 33 40 33 …
All 44 33 77 70 90.9
Microscopic examination
Positive 56 5d 61 56 …
Negative 2d 33 35 33 …
All 58 38 96 89 92.7
NOTE. Data are no. of specimens, unless otherwise indicated. DITM, Department of Infectious
Diseases and Tropical Medicine (Munich, Germany); KCCR, Kumasi Centre for Collaborative Research
in Tropical Medicine (Kumasi, Ghana). Microscopic examination was performed for 96 slides at KCCR,
and the slides were reexamined by staff at DITM.
a No. of specimens with concordant results divided by the total number of specimens tested with
the same test at KCCR and DITM.
b PCR was performed with parallel testing of 77 DNA extracts. Dry reagent–based IS2404 PCR
was performed at KCCR; standard PCR was performed at DITM.
c Dry reagent–based PCR performed at KCCR gave false-positive results for 0 (0%) of the spec-
imens tested and false-negative results for 7 (9.1%) of the specimens tested.
d Microscopic examination performed at KCCR gave false-positive results for 5 (5.2%) of the
specimens tested and false-negative results for 2 (2.1%) of the specimens tested.
nation and culture plus confirmatory IS2404 PCR ( )Pp .054
(table 3).
Sensitivities of laboratory tests among confirmed BUD cases
involving nonulcerative lesions. Among 114 confirmed non-
ulcerative BUD cases (drug treatment group, 92 cases; surgical
treatment group, 15 cases; surgical treatment plus antimyco-
bacterial treatment group, 7 cases), the sensitivities were 89.5%
(102 of 114 specimens) for PCR, 57.0% (65 of 114 specimens)
for microscopic examination, and 60.6% (57 of 94 specimens)
for culture plus confirmatory IS2404 PCR analysis of tissue
specimens. PCR was significantly more sensitive than micro-
scopic examination and culture plus confirmatory IS2404 PCR
( for each). Stratified into treatment groups and speci-P ! .01
mens, the sensitivities for analysis of punch biopsy tissue spec-
imens from the drug treatment group were 93.5% for PCR and
70.8% for culture plus confirmatory IS2404 PCR, which was
statistically significantly higher than that for surgically excised
tissue specimens in the surgical treatment group (table 3).
Sensitivities of laboratory tests among patients with con-
firmed BUD and ulcerative lesions. Among 154 laboratory-
confirmed cases of ulcerative BUD (drug treatment group, 68
cases; surgical treatment group, 44 cases; surgical treatment plus
antimycobacterial therapy group, 42 cases), the sensitivities
were 69.8% (169 of 242 specimens) for PCR, 44.6% (108 of
242 specimens) for microscopic examination, and 25.0% (52
of 208 specimens) for culture plus confirmatory IS2404 PCR
analysis of swab samples and tissue specimens. PCR was sta-
tistically significantly more sensitive than microscopic exami-
nation and culture plus confirmatory IS2404 PCR (P ! .01
each). Stratified into treatment groups and specimens, the sen-
sitivities for PCR analysis of swab specimens were 89.9% for
the drug treatment group, 73.1% for the surgical treatment
group, and 72.2% for the surgical treatment plus antimyco-
bacterial therapy group. In all treatment groups, PCR sensitivity
was greater for swab samples than it was for punch biopsy
tissue specimens (67.8%) or surgically excised tissue specimens
(surgical treatment group, 57.7%; surgical treatment plus an-
timycobacterial therapy group, 44.4%) (table 3).
Sensitivities of laboratory tests among patients with ulcer-
ative lesions without previous antimycobacterial treatment de-
pending on the duration of disease. According to duration
of disease, 101 patients with laboratory-confirmed, previously
untreated cases of BUD with ulcerative lesions were divided
into 5 groups. In all groups, PCR of swab samples had a sta-
tistically significantly higher sensitivity (70%–91%) than did
microscopic examination of swab samples (30%–67%) or cul-
ture plus confirmatory IS2404 PCR of swab samples (29%–
59%). Despite a slight downward trend, no statistically signif-
icant association between test sensitivity and duration of disease
for any test was found (figure 3).
Test sensitivity depending on duration of previous anti-
mycobacterial treatment. In the 49 laboratory-confirmed
cases of BUD in the surgical treatment plus antimycobacterial
treatment group (7 nonulcerative case and 42 ulcerative cases),
the test sensitivity was correlated with the duration of previous
antimycobacterial treatment. Regardless of treatment duration,
PCR was always the test with the highest sensitivity. The sen-
sitivities of PCR and culture plus confirmatory IS2404 PCR
were statistically significantly higher in the group of untreated
patients than in the group of patients treated for 140 days (for
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Figure 3. Sensitivity of diagnostic tests (dry reagent–based [DRB] IS2404 PCR, microscopic examination, and culture plus confirmatory DRB IS2404
PCR) by duration of disease among 112 patients with laboratory-confirmed Buruli ulcer disease and ulcerative lesions who had not received previous
antibiotic treatment (68 swab specimens from patients in the drug treatment group and 44 swab specimens from patients in the surgical treatment
without prior antimycobacterial therapy group). No patient reported a 7–9-month duration of disease.
PCR) or 120 days (for culture plus confirmatory IS2404 PCR).
No statistically significant difference was found for microscopic
examination (figure 4).
DISCUSSION
This is, to our knowledge, the largest study to date to evaluate
the diagnostic yield of various diagnostic tests after the intro-
duction of antimycobacterial therapy in a West African region
in which BUD is highly endemic. Diagnostic tests proved to
be reliable within a range of disease durations and across a
range of clinical presentations and treatment groups. The results
are relevant for case definition for drug trials. Furthermore,
locally conducted laboratory confirmation may improve the
reliability of epidemiological data.
The majority of recent data on the laboratory confirmation
of clinically suspected BUD are from the era when surgical
excision was considered to be the standard treatment, when
surgically excised tissue specimens accounted for the majority
of specimens analyzed. Following the introduction of anti-
mycobacterial treatment, swab samples and punch biopsy tissue
specimens, which provide the possibility of pretreatment di-
agnosis, have become increasingly important. Surgical excision
and subsequent skin grafting, however, are still used to treat
patients who experience treatment failure and have lesions that
do not heal completely after antimycobacterial therapy. In these
cases, surgically excised tissue specimens are available for lab-
oratory analysis.
Comparable with previous data [20], laboratory confirma-
tion by 1 positive test result gave 26% more confirmed cases
than did confirmation by at least 2 positive test results. As in
previous studies, histopathological examination identified an
additional ∼30% of cases, mainly in patients whose disease was
in the paucibacillary stage [14, 19, 20]. However, histopatho-
logical features may not provide unambiguous identification,
and the availability of the method is limited [11, 14, 19, 20].
Findings obtained with follow-up samples suggest retesting of
patients who have typical clinical features but initial laboratory
results that are negative.
The overall sensitivities of dry reagent–based PCR (85%),
microscopic examination (57%), and culture plus confirmatory
IS2404 PCR (48%), as determined in our study, are comparable
with data published by other groups [8–15]. Independently of
treatment group, type of lesion, or diagnostic specimen, the
overall sensitivity of PCR was statistically significantly (P !
) higher than that of any other test, whereas there was no.01
statistically significant difference between microscopic exami-
nation and culture plus confirmatory IS2404 PCR ( ).Pp .054
The majority of mycobacterial isolates were confirmed to be
M. ulcerans by IS2404 PCR or other methods. However, a few
study patients, most of whom had received antimycobacterial
treatment, harbored other mycobacteria. Because these strains
were only isolated from these patients, laboratory contamina-
tion is unlikely. In the absence of other confirmatory tests or
persistent mycobacterial growth after drug treatment, confir-
mation by molecular methods is important to identify coin-
fections or superinfections due to other mycobacteria.
Stratification by lesion type and treatment group gave the
following major findings. The sensitivity (93.5%) of PCR per-
formed on 3-mm punch biopsy tissue specimens obtained from
previously untreated patients in the drug treatment group who
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Figure 4. Sensitivity of diagnostic tests (dry reagent–based [DRB] IS2404 PCR, microscopy, and culture plus confirmatory DRB IS2404 PCR) among
49 patients with laboratory-confirmed cases of Buruli ulcer disease who received surgical treatment with previous antimycobacterial treatment (7 with
preulcerative and 42 with ulcerative lesions), stratified by duration of previous antimycobacterial treatment (3–20 days, 9 patients; 21–40 days, 30
patients; 40 days, 10 patients). A total of 219 patients received no treatment.
had nonulcerative lesions was significantly higher than the sen-
sitivity of any other diagnostic test. These data are in line with
the 98.3% sensitivity of PCR of 4-mm and 6-mm punch biopsy
tissue specimens determined by Phillips et al. [23]. Culture plus
confirmatory IS2404 PCR of punch biopsy tissue specimens
also provided an excellent sensitivity of 70.8% among patients
with BUD who had nonulcerative lesions. Therefore, 3-mm
punch biopsy tissue specimens can be recommended for the
pretreatment diagnosis of patients with nonulcerative lesions
before initiation of antimycobacterial therapy. However, the
small size of punch biopsy tissue specimens hampers histo-
pathological analysis [29].
In previous studies in Ghana, PCR of swab samples con-
firmed 60%–70% of suspected cases of BUD with ulcerative
lesions [14, 20]. The data on the sensitivity of PCR of swab
samples obtained in this study also suggest considering PCR
analysis of diagnostic swab samples to be the method of choice
for cases that involve ulcerative lesions. Especially among the
previously untreated patients in the drug treatment group with
ulcerative early lesions, PCR of swab samples (sensitivity,
89.9%) proved to be superior to PCR analysis of 3-mm punch
biopsy tissue specimens (sensitivity, 67.8%). In the surgical
treatment group and the surgical treatment plus antimycobac-
terial treatment group, PCR of swab samples also had higher
sensitivity than did analysis of tissue specimens. In accordance
with previous observations, the lower sensitivity for tissue spec-
imens obtained from patients who underwent surgery may be
attributable to difficulties in determining the correct location
for specimen collection once tissue is excised [14].
Despite a slight downward trend, no statistically significant
association between duration of disease and diagnositic sen-
sitivity was detected for swab specimens in this study. However,
according to our own experience, in the course of the disease,
the edges of ulcers often develop scarring, which can hinder
the collection of swab samples. The duration of antimycobac-
terial treatment influenced the diagnostic sensitivities of PCR
and culture plus confirmatory IS2404 PCR. Compared with
their sensitivity in untreated patients, the sensitivities of both
tests were statistically significantly lower after treatment. A sta-
tistically significant decrease in culture sensitivity was detected
after 20 days of treatment. More than 40 days of treatment
were required to produce the same effect for PCR. In pretreated
patients, the sensitivity of PCR was still 50%, whereas the sen-
sitivity of culture plus confirmatory IS2404 PCR decreased to
6%. In contrast with the rapid decrease in the viability of M.
ulcerans in the first weeks after onset of treatment, PCR findings
suggest extended persistence of M. ulcerans DNA in treated
lesions.
This study describes the relative sensitivity of currently avail-
able diagnostic tests. Data on the specificity and the positive
predictive values of these tests cannot be provided, because
analysis of diagnostic samples from healthy individuals (in-
cluding tissue specimens) would have been required to deter-
mine the number of false-positive test results. Assessment of
positive and negative predictive values requires comparison
with a reference test. Because of the limited availability of ref-
erence methods (e.g., histopathological examination as a ref-
erence test for PCR), the determination of positive and negative
predictive values was not feasible for the entire range of tests
used in this study.
According to the results of this study, IS2404 PCR was the
test with the highest sensitivity overall and in all subgroups of
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this study cohort; therefore, it is most suitable for the early
diagnosis of all clinical forms of BUD. For monitoring of an-
timycobacterial treatment success within controlled trials, how-
ever, only culture seems to be the appropriate tool.
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